Volastra Therapeutics: Funding, Investors & Team (Oct 2026)
Volastra Therapeutics is a biotechnology company that is creating new treatments for metastatic cancer by leveraging specific knowledge about chromosomal instability.
Volastra Therapeutics has raised $105M across 3 funding rounds on record, the most recent an undisclosed round of $30.1M announced in Sep 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Volastra Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2025.
Volastra Therapeutics Funding Rounds
Volastra Therapeutics raised $60.0M in a Series A announced in Mar 2023.
1.2 years later, an undisclosed round of $15.0M was announced in May 2024.
1.3 years later, an undisclosed round of $30.1M was announced in Sep 2025.
Volastra Therapeutics Founders and Leadership Team
Contact details for the Volastra Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Volastra Therapeutics Funding Compared to Other Biotechnology Startups
Volastra Therapeutics' latest round of $30.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Volastra Therapeutics in Biotechnology and New York
Companies Similar to Volastra Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Volastra Therapeutics Funding FAQs
What does Volastra Therapeutics do?
Volastra Therapeutics is a biotechnology company that is creating new treatments for metastatic cancer by leveraging specific knowledge about chromosomal instability.
How much funding has Volastra Therapeutics raised?
Volastra Therapeutics has raised $105M across 3 rounds on record. The most recent is an undisclosed round of $30.1M announced in Sep 2025.
When did Volastra Therapeutics last raise funding?
Volastra Therapeutics' most recent funding round on record is an undisclosed round of $30.1M, announced in Sep 2025.
Who founded Volastra Therapeutics?
FundedIQ lists Samuel Bakhoum (Founder) at Volastra Therapeutics.
Who is the CEO of Volastra Therapeutics?
David P. Southwell is listed as CEO at Volastra Therapeutics.
Where is Volastra Therapeutics headquartered?
Volastra Therapeutics is based in New York, United States.
How many employees does Volastra Therapeutics have?
Volastra Therapeutics is in the 11-50 employee band.
How does Volastra Therapeutics' funding compare to other Biotechnology startups?
Volastra Therapeutics' latest round of $30.1M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Volastra Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Volastra Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.